BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35931675)

  • 1. Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching.
    Chen C; Zhao S; Zhao X; Cao L; Karnad A; Kumar AP; Freeman JW
    Cell Death Dis; 2022 Aug; 13(8):682. PubMed ID: 35931675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy.
    Zhao S; Chen C; Chang K; Karnad A; Jagirdar J; Kumar AP; Freeman JW
    Clin Cancer Res; 2016 Nov; 22(22):5592-5604. PubMed ID: 27267855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells.
    Hong SP; Wen J; Bang S; Park S; Song SY
    Int J Cancer; 2009 Nov; 125(10):2323-31. PubMed ID: 19598259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
    Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
    Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and characterization of gemcitabine-resistant pancreatic tumor cells.
    Shah AN; Summy JM; Zhang J; Park SI; Parikh NU; Gallick GE
    Ann Surg Oncol; 2007 Dec; 14(12):3629-37. PubMed ID: 17909916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GABRP promotes CD44s-mediated gemcitabine resistance in pancreatic cancer.
    Chen C; Wu B; Wang M; Chen J; Huang Z; Shi JS
    PeerJ; 2022; 10():e12728. PubMed ID: 35846884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
    Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y
    Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor 1 receptor promotes the growth and chemoresistance of pancreatic cancer.
    Tian X; Hao K; Qin C; Xie K; Xie X; Yang Y
    Dig Dis Sci; 2013 Sep; 58(9):2705-12. PubMed ID: 23589145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
    Sumiyoshi H; Matsushita A; Nakamura Y; Matsuda Y; Ishiwata T; Naito Z; Uchida E
    Oncol Rep; 2016 Jun; 35(6):3216-26. PubMed ID: 27035235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
    Ma J; Fang B; Zeng F; Ma C; Pang H; Cheng L; Shi Y; Wang H; Yin B; Xia J; Wang Z
    Oncotarget; 2015 Jan; 6(3):1740-9. PubMed ID: 25638153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs).
    Wang L; Zhang Y; Wang W; Zhu Y; Chen Y; Tian B
    PLoS One; 2017; 12(8):e0184110. PubMed ID: 28854261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.
    Tu M; Li H; Lv N; Xi C; Lu Z; Wei J; Chen J; Guo F; Jiang K; Song G; Gao W; Miao Y
    Mol Cancer; 2017 Mar; 16(1):66. PubMed ID: 28327155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
    Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
    Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling.
    Liu X; Tian X; Wang F; Ma Y; Kornmann M; Yang Y
    Eur J Cancer; 2014 Sep; 50(13):2251-62. PubMed ID: 24953335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrin β1 promotes gemcitabine resistance in pancreatic cancer through Cdc42 activation of PI3K p110β signaling.
    Yang D; Tang Y; Fu H; Xu J; Hu Z; Zhang Y; Cai Q
    Biochem Biophys Res Commun; 2018 Oct; 505(1):215-221. PubMed ID: 30243721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
    Rajabpour A; Afgar A; Mahmoodzadeh H; Radfar JE; Rajaei F; Teimoori-Toolabi L
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):765-775. PubMed ID: 28887583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine resistance induced by interaction between alternatively spliced segment of tenascin-C and annexin A2 in pancreatic cancer cells.
    Gong XG; Lv YF; Li XQ; Xu FG; Ma QY
    Biol Pharm Bull; 2010; 33(8):1261-7. PubMed ID: 20686216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rab14 overexpression regulates gemcitabine sensitivity through regulation of Bcl-2 and mitochondrial function in pancreatic cancer.
    Ge J; Ge C
    Virchows Arch; 2019 Jan; 474(1):59-69. PubMed ID: 30267303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CD44 standard isoform contributes to radioresistance of pancreatic cancer cells.
    Tsubouchi K; Minami K; Hayashi N; Yokoyama Y; Mori S; Yamamoto H; Koizumi M
    J Radiat Res; 2017 Nov; 58(6):816-826. PubMed ID: 29106581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.